For Report Sample Contact: neeraj@kuickresearch.com
Report Weblink:https://www.kuickresearch.com/report-global-cancer-mtor-inhibitors-market-and-clinical-pipeline-outlook-2022.php
Table of Contents
1. Mammalian Target of Rapamycin Inhibitors (mTOR) – The Future of Cancer Growth Blockers
1.1 Preliminary Insight to mTOR Inhibitors
1.2 History and Evolution of the mTOR Inhibitors
2. mTOR Signalling Pathway: Their Role and Significance in Cancer
2.1 mTOR Signalling: A Vital Function in Cell Growth
2.2 mTOR Signalling Pathway and Tumorigenesis
3. Principles of mTOR inhibitors in Cancer Therapy
3.1 Activation of mTOR/pI3K pathway in Cancer
3.2 Potential of mTOR as a Targeted Therapy
3.3 Global – Cancer MTOR Inhibitors Clinical Pipeline Overview
4. Working Mechanism of mTOR Inhibitors in Cancer Therapy
4.1 Effect of mTOR inhibitors in Cancer Cells
4.2 Effects of mTOR inhibitors on Tumor Angiogenesis
5. Clinical Status and Application of mTOR inhibitors in Various Types of Cancer
5.1 Breast Cancer
5.1.1 HER2-Positive Breast Cancer
5.1.2 HER-2 Negative Breast Cancer
5.2 Hematological Malignancy
5.2.1 Acute Myeloid Leukemia
5.2.2 Chronic Myelogenous Leukemia
5.2.3 Acute Lymphoblastic Leukemia
5.2.4 Multiple Myeloma
5.2.5 Lymphoma
5.3 Neuroendocrine Tumors
5.4 Hepatocellular Carcinoma
5.5 Glioblastoma (Brain Tumor)
5.6 Other Cancers/Tumors Where mTOR Inhibitors Could be Effective
5.6.1 Non-small Cell Lung Cancers
5.6.2 Colon Cancer
6. Recent Advances in mTOR Inhibitor Cancer Therapy
6.1 Drug Combinations as a Therapeutic Approach for mTORC1 Inhibitors in Human Cancer
6.2 Optimizing Activity of Rapalogs Using Combinations with Other Anticancer Drugs
7. Global Demand and Opportunities in the mTOR Inhibitor Market
8. Global andndash; Cancer MTOR Inhibitors Clinical Pipeline by Company, Indication and Phase
8.1 Research
8.2 Preclinical
8.3 Phase-I
8.4 Phase-I/II
8.5 Phase-II
8.6 Phase-III
9. Marketed Cancer MTOR Inhibitors Clinical Insight
9.1 Temsirolimus (Torisel)
9.2 Everolimus (Absorb, Affinitor, Affinitor Dispersible, Afinitor, Afinitor Disperz, Certican, Esprit BVS, Promus, Promus Element, Promus Premier, Synergy, Votubia, Xience Prime, Xience V, Xience Xpedition, Xience nano and Zortress)
10. mTOR Inhibitor andndash; Price Analysis by Under Development and Approved Inhibitors
10.1 mTOR Inhibitors Price by Product Under Development
10.1.1 Dactolisib(BEZ 235, NVP-BEZ 235)
10.1.2 Rapamycin
10.1.3 Temsirolimus
10.1.4 PI-103
10.1.5 AZD 8055
10.1.6 Torkinib (pp242)
10.1.7 Ridaforolimus (Deforolimus, MK-8669)
10.1.8 MLN0128 (INK128)
10.1.9 Omipalisib (GSK2126458, GSK458)
10.1.10 Gedatolisib (PF-05212384, PKI-587)
10.1.11 Other Promising mTOR Inhibitors
10.2 Approved and Commercialized Cancer Therapy mTOR Inhibitor Price Analysis
10.2.1 Afinitor/Votubia
10.2.2 Afinitor Disperz andndash; mTOR inhibitor for Rare Pediatric Brain Tumor
10.2.3 Torisel (Temsirolimus)
10.2.4 Evertor andndash; Everolimus by Biocon
11. Market Performance Analysis of mTOR Inhibitors
11.1 Market Performance by Industry
11.1.1 Afinitor by Novartis
11.1.2 Toricel by Pfizer
11.1.3 Evertor by Biocon
12. Comparative Cost Analysis of mTOR Inhibitors with Other Cancer Therapeutics
12.1 Comparative Cost Analysis by other Popular Cancer Therapy Drugs
12.2 Comparative Cost Analysis with Traditional Cancer Therapeutics
13. Regional Analysis of mTOR Inhibitor Market
13.1 North America
13.2 Europe
13.3 Asia Pacific
13.4 Rest of the World
14. Global mTOR Inhibitor Market Dynamics
14.1 Driving Factors of the Global mTOR Inhibitor Market
14.2 Restraining Factors of the Global mTOR Inhibitor Market
15. Future Forecast and Growth Projections of Global mTOR Inhibitors Market
16. Competitive Landscape
16.1 Abraxis BioScience
16.2 Adimab
16.3 Celgene Corporation
16.4 Celator Pharmaceuticals
16.5 Eli Lilly
16.6 Exelixis
16.7 GlaxoSmithKline
16.8 HEC Pharm
16.9 Intellikine
16.10 Novartis
16.11 Oneness Biotech
16.12 PIQUR Therapeutics
16.13 Semafore Pharmaceuticals
16.14 Takeda
16.15 Wyeth
Figure 1-1: mTOR Inhibitors Timeline
Figure 2-1: Normal Functioning of the mTOR Pathway
Figure 3-1: Activators of the mTOR Pathway
Figure 3-2: Global andndash; Cancer MTOR Inhibitors Clinical Pipeline by Phase (%), 2017 till 2022
Figure 3-3: Global andndash; Cancer MTOR Inhibitors Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 3-4: Global andndash; Cancer MTOR Inhibitors Clinical Pipeline by Phase (%), 2017 till 2022
Figure 3-5: Global andndash; Cancer MTOR Inhibitors Clinical Pipeline by Phase (Number), 2017 till 2022
Figure 4-1: mTOR Inhibitors in Action
Figure 5-1: mTOR inhibitors in Breast Cancer
Figure 5-2: The mTOR (PAM) Pathway and Inhibitors of the pathway tested in phase I-III Clinical Trials on Solid Tumors and Breast Cancer
Figure 5-3: Action of Inhibitors under Clinical Development
Figure 6-1: Higher Efficacy of Therapeutics Achieved by using mTOR inhibitor in Combination
Figure 7-1: Global – Breast Cancer Incidence (Per 100,000 females), 2016
Figure 7-2: Global – Kidney Cancer Prevalence (Total Incidence Recorded), 2016
Figure 7-3: Global-Hepatocellular Carcinoma by Region ( per 100, 000),2016
Figure 10-1: Dactolisib- Price Analysis (US$/mg),2017
Figure 10-2: Rapamycin – Price Analysis (US$/mg), 2017
Figure 10-3: Temsirolimus – Price Analysis (US$/gm.), 2017
Figure 10-4: PI-103 Price Analysis (US$/gm.), 2017
Figure 10-5: AZD 8055-Price analysis (US$/mg), 2017
Figure 10-6: Torkinib-Price Analysis (US $/mg), 2017
Figure 10-7: Ridaforolimus- Price Analysis (US$/mg), 2017
Figure 10-8: MLNO 128- Price Analysis (US$/mg), 2017
Figure 10-9: Omipalisib – Price Analysis (US$/mg), 2017
Figure 10-10: Gedatolisib – Price Analysis (US$/mg), 2017
Figure 10-11: Apitolisib (GDC-0980, RG7422) – Price Analysis (US$/mg), 2017
Figure 10-12: Vistusertib-(AZD2014 (GDC-0980, RG7422) – Price Analysis (US$/mg), 2017
Figure 10-13: Voxtalisib -AZD2014 (GDC-0980, RG7422) – Price Analysis (US$/mg), 2017
Figure 10-14: OSI-27 price analysis (US$/mg), 2017
Figure 10-15: US – Price Analysis of Afinitor by quantity (28 Tablet Packet), 2017
Figure 10-16: Price Analysis- Everolimus Standalone Therapy (US$), 2017
Figure 10-17: Afinitor Disperz – Price Analysis by Quantity (US$), 2017
Figure 10-18: Temsirolimus – Cost Analysis (US$), 2017
Figure 10-19: Cost Analysis andndash; Evertor (Everolimus by Biocon)(US$), 2017
Figure 11-1: Global andndash; Afinitor Sales (US$ Million), 2013-2016
Figure 11-2: Global – Toricel Sales (US$ Million), 2012-2016
Figure 11-3: Global andndash; Evertor Sales (US$ Million), 2012-2016
Figure 12-1: Comparative Cost Analysis andndash; Afinitor (mTOR inhibitor) v/s Other Recommended Therapy for Breast Cancer (US$/Month), 2017
Figure 12-2: Comparative Cost Analysis andndash; Everolimus and Temsirolimus (mTOR inhibitors) v/s Other Recommended Therapy for Kidney Cancer (US$/Month), 2017
Figure 12-3: Comparative Cost Analysis andndash; Average mTOR Inhibitor Therapy v/s Traditional Cancer Therapy Cost
Figure 13-1: Global- mTOR Inhibitor Market by Region (%), 2016 and 2022
Figure 14-1: Global – Driving Factors of the mTOR Inhibitor Market
Figure 14-2: Global – Challenging Factors of the Global mTOR Inhibitor Market
Figure 14-3: Afinitor – Patent Expiration, 2017-2020
